|
1
|
Matte P, Delaye M, Mc Govern A, Rouby P, Ponce S, Lemogne C, Baldini C. Exclusion of patients with psychiatric disorders from early phase oncology trials: A limited access to innovation? Gen Hosp Psychiatry 2024; 87:164-165. [PMID: 38220547 DOI: 10.1016/j.genhosppsych.2024.01.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Revised: 12/30/2023] [Accepted: 01/08/2024] [Indexed: 01/16/2024]
Affiliation(s)
- Paul Matte
- Drug Development Department (DITEP), Paris Saclay University, Gustave Roussy, Villejuif, France.
| | - Matthieu Delaye
- Drug Development Department (DITEP), Paris Saclay University, Gustave Roussy, Villejuif, France
| | - Alice Mc Govern
- Child and Adolescent Psychiatry Department, Robert Debré Hospital, APHP, 48 boulevard Sérurier, 75019 Paris, France
| | - Pascal Rouby
- Psycho-Oncology Unit, Paris Saclay University, Gustave Roussy, Villejuif, France
| | - Santiago Ponce
- Drug Development Department (DITEP), Paris Saclay University, Gustave Roussy, Villejuif, France
| | - Cédric Lemogne
- Université Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), F-75004 Paris, France; Service de Psychiatrie de l'adulte, AP-HP, Hôpital Hôtel-Dieu, F-75004 Paris, France
| | - Capucine Baldini
- Drug Development Department (DITEP), Paris Saclay University, Gustave Roussy, Villejuif, France
| |
Collapse
|